Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - mesuximidum - capsule - mesuximidum 300 mg, colore.: di e 104, e 110, excipiens per la capsula. - antiepilepticum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - acido mefenamicum - capsule rigide - acidum mefenamicum 250 mg, gelatina, lactosum monohydricum 77.61 mg, natrii laurilsulfas, kapselhülle: gelatina, e 132, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula corresp. natrium 93 µg. - analgeticum, antipyreticum, antiphlogisticum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - estramustini phosphas - capsule - estramustini phosphas 140 mg ut estramustini phosphas dinatricus monohydricus, talcum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula corresp. natrium 12.53 mg. - della prostata carcinoma - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - acipimoxum - capsule rigide - acipimoxum 250 mg, amylum pregelificatum, silica colloidalis, magnesii stearas, natrii laurilsulfas corresp. natrium 0.05 mg, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum) pro capsula. - lipidsenker - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - rifabutinum - capsule - rifabutinum 150 mg, excipiens pro capsula. - mycobakterieninfektionen - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - agenti antineoplastici - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - clindamycinum - granulato per la realizzazione di una soluzione orale - clindamycinum 75 mg ut clindamycini-2 palmitatis hydrochloridum, simeticonum, poloxamerum 188, saccharum 1.8 g, aromatica (kirschen), e 214 0.6 mg ad granulatum corresp. solutio reconstituta 5 ml. - malattie infettive - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

pfizer italia s.r.l. - voriconazolo - voriconazolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

pfizer italia s.r.l. - sumatriptan - sumatriptan

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

pfizer italia s.r.l. - pravastatina - pravastatina